AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone386-462-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$83.94 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
AxoGen (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc (NASDAQ:AXGN) posted its earnings results on Tuesday, August, 6th. The medical equipment provider reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The medical equipment provider earned $26.70 million during the quarter, compared to analyst estimates of $26.77 million. AxoGen had a negative net margin of 26.91% and a negative return on equity of 16.73%. AxoGen's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.09) earnings per share. View AxoGen's Earnings History.
When is AxoGen's next earnings date?
What guidance has AxoGen issued on next quarter's earnings?
AxoGen issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $106-110 million, compared to the consensus revenue estimate of $111.89 million.
What price target have analysts set for AXGN?
6 Wall Street analysts have issued twelve-month price targets for AxoGen's stock. Their forecasts range from $21.00 to $55.00. On average, they anticipate AxoGen's stock price to reach $31.00 in the next year. This suggests a possible upside of 94.2% from the stock's current price. View Analyst Price Targets for AxoGen.
What is the consensus analysts' recommendation for AxoGen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.
What are Wall Street analysts saying about AxoGen stock?
Here are some recent quotes from research analysts about AxoGen stock:
- 1. BTIG Research analysts commented, "Raise PT to $29 We reiterate our Buy rating and raise our price target to $29 (from $28) following 1Q19 results. 1Q19 results beat both BTIG and Consensus est. with rev. of $23.3M (+34.9% Y/Y) coming in ahead of (~29% implied). Expenses were elevated as one-timers, increasing sales reps, and costs associated with RECON stepped up, but mgmt. expects these costs to moderate through the year. When we upgraded AXGN intra-quarter (here), the crux of our thesis was that improved stability and hiring trends in the sales force following the leadership transition would lead to more consistent execution and allow AXGN to return to improved growth. Thus far, results are playing out as we surmised but we acknowledge it’s still early in the year." (5/10/2019)
- 2. Cantor Fitzgerald analysts commented, "We think AXGN is one of the most compelling growth stories in medtech, with what we believe is sustainable top-line growth of north of 30% for the next two years. We expect utilization to accelerate as favorable clinical and economic data builds and increases surgeon awareness. We would also expect the company to continue to pursue additional market opportunities, as the technology is applicable to nerves across the body. Valuation Summary We value AXGN using a 6x EV/Sales multiple on our 2020 sales estimate to arrive at our 12-month price target of $26." (1/18/2019)
Has AxoGen been receiving favorable news coverage?
News headlines about AXGN stock have been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AxoGen earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for AxoGen.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include Natus Medical (BABY), Natus Medical (NTUS), IntegraMed America, Incorporation. (INMD), TransMedics Group (TMDX), Cutera (CUTR), Viewray (VRAY), BioLife Solutions (BLFS), Zynex (ZYXI), Semler Scientific (SMLR), Stereotaxis (STXS), BioSig Technologies (BSGM), Fonar (FONR), Rockwell Medical (RMTI), Second Sight Medical Products (EYES) and Edap Tms (EDAP).
What other stocks do shareholders of AxoGen own?
Who are AxoGen's key executives?
AxoGen's management team includes the folowing people:
- Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
- Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
- Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
- Mr. Michael Donovan, VP of Operations (Age 54)
- Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.
Who are AxoGen's major shareholders?
AxoGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.81%), Essex Woodlands Management Inc. (6.19%), Vanguard Group Inc. (4.51%), Bank of New York Mellon Corp (2.81%), Baillie Gifford & Co. (2.50%) and Bank of America Corp DE (1.95%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, David K Hansen, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.
Which institutional investors are selling AxoGen stock?
AXGN stock was sold by a variety of institutional investors in the last quarter, including Essex Woodlands Management Inc., Artemis Investment Management LLP, Eagle Asset Management Inc., Marshall Wace LLP, Granite Point Capital Management L.P., Russell Investments Group Ltd., Susquehanna International Group LLP and NumerixS Investment Technologies Inc. Company insiders that have sold AxoGen company stock in the last year include David K Hansen, Gregory Gene Freitag, Karen L Zaderej and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.
Which institutional investors are buying AxoGen stock?
AXGN stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, D. E. Shaw & Co. Inc., Point72 Asset Management L.P., BlackRock Inc., Peregrine Capital Management LLC, Nuveen Asset Management LLC, Bank of America Corp DE and Great Lakes Advisors LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.
How do I buy shares of AxoGen?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AXGN stock can currently be purchased for approximately $15.96.
How big of a company is AxoGen?
AxoGen has a market capitalization of $626.59 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.
What is AxoGen's official website?
How can I contact AxoGen?
AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen (NASDAQ AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
